Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…

Program provides access to real-world data to refine AI algorithms for earlier detection of complex heart conditions

Simultaneous publication in Journal of the American College of Cardiology demonstrates impact of ECG-AI on heart failure risk assessment. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in AI-powered cardiovascular diagnostics, today announced…

Wall Street Journal: At Mayo cardiology, an AI tool has helped doctors diagnose new cases of heart failure and cases of irregular heart rhythms, which are called atrial fibrillation, potentially…